Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Issue 9 (September 2020)

• Record Type: Journal Article
• Authors: Simon, James A.; Al-Hendy, Ayman; Archer, David F.; Barnhart, Kurt T.; Bradley, Linda D.; Carr, Bruce R.; Dayspring, Thomas; Feinberg, Eve C.; Gillispie, Veronica; Hurtado, Sandra; Kim, JinHee; Liu, Ran; Owens, Charlotte D.; Muneyyirci-Delale, Ozgul; Wang, Alice; Watts, Nelson B.; Schlaff, William D.
• Is Part Of: Obstetrical & gynecological survey. Volume 75:Issue 9(2020)
• Publication Date: 2020-09
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000696612.60869.1b
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from Obstet Gynecol 2020;135:1313–1326) Uterine leiomyomas affect up to 80% of reproductive-age women and are the most common benign neoplasm of the uterus. A variety of symptoms occur in approximately half of these women; the most common is heavy menstrual bleeding (HMB), which can result in anemia.